Clinical trial
A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
NCT03914612 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
- Lead sponsor
- National Cancer Institute (NCI)
- Phase
- Phase 3
- Overall status
- Active, not recruiting
- Start date
- August 22, 2019
- Completion date
- September 26, 2026
- Enrollment
- 813 (actual)
- Sites
- 397
Conditions
As the registry lists them; a condition with its own page is linked.
endometrial clear cell adenocarcinoma, endometrial dedifferentiated carcinoma, endometrial endometrioid adenocarcinoma, endometrial mixed cell adenocarcinoma, endometrial serous adenocarcinoma, endometrial undifferentiated carcinoma, recurrent endometrial adenocarcinoma, recurrent endometrial carcinoma, recurrent endometrial clear cell adenocarcinoma, recurrent endometrial dedifferentiated carcinoma, recurrent endometrial endometrioid adenocarcinoma, recurrent endometrial mixed cell adenocarcinoma, recurrent endometrial serous adenocarcinoma, recurrent endometrial undifferentiated carcinoma, stage iii uterine corpus carcinoma or carcinosarcoma ajcc v8, stage iv uterine corpus carcinoma or carcinosarcoma ajcc v8